-
Something wrong with this record ?
Pharmacodynamic profiling in three patients with molybdenum cofactor deficiency type A reveals prolonged biological effects after withdrawal of cyclic pyranopterin monophosphate
BC. Schwahn, K. Barvíková, HT. Wu, A. Horman, E. Emmett, V. Kožich
Language English Country United States
Document type Journal Article, Case Reports
- MeSH
- Child MeSH
- Infant MeSH
- Humans MeSH
- Metalloproteins deficiency metabolism genetics MeSH
- Molybdenum Cofactors MeSH
- Organophosphorus Compounds MeSH
- Child, Preschool MeSH
- Pterins MeSH
- Sulfite Oxidase deficiency metabolism genetics MeSH
- Metal Metabolism, Inborn Errors * drug therapy genetics MeSH
- Xanthine Dehydrogenase * deficiency metabolism genetics MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
Molybdenum cofactor deficiency type A has successfully been treated in a small number of children with daily intravenous administration of cyclic pyranopterin monophosphate. Pharmacodynamic data for this novel treatment have not been published and alternative dosing intervals have not been explored. We monitored pharmacodynamic biomarkers of sulfite oxidase and xanthine oxidoreductase activity in three patients with MoCD-A for a period of 2 to 9 months after discontinuation of cPMP substitution. We found that the clinical and metabolic effects were sustained for longer than expected, over 7 days at least. Our data implicate a biological half-life of the molybdenum cofactor dependent enzyme activities of approximately 3 days and suggest the possibility that less frequent than once daily dosing intervals could be a safe alternative to current practice.
Biochemical Sciences Synnovis Guys and St Thomas' NHS Foundation Trust London UK
Department of Chemical Pathology Great Ormond Street Hospital London UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004124
- 003
- CZ-PrNML
- 005
- 20250206105138.0
- 007
- ta
- 008
- 250121s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ymgme.2024.108563 $2 doi
- 035 __
- $a (PubMed)39168057
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Schwahn, B C $u Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK. Electronic address: Bernd.schwahn@mft.nhs.uk
- 245 10
- $a Pharmacodynamic profiling in three patients with molybdenum cofactor deficiency type A reveals prolonged biological effects after withdrawal of cyclic pyranopterin monophosphate / $c BC. Schwahn, K. Barvíková, HT. Wu, A. Horman, E. Emmett, V. Kožich
- 520 9_
- $a Molybdenum cofactor deficiency type A has successfully been treated in a small number of children with daily intravenous administration of cyclic pyranopterin monophosphate. Pharmacodynamic data for this novel treatment have not been published and alternative dosing intervals have not been explored. We monitored pharmacodynamic biomarkers of sulfite oxidase and xanthine oxidoreductase activity in three patients with MoCD-A for a period of 2 to 9 months after discontinuation of cPMP substitution. We found that the clinical and metabolic effects were sustained for longer than expected, over 7 days at least. Our data implicate a biological half-life of the molybdenum cofactor dependent enzyme activities of approximately 3 days and suggest the possibility that less frequent than once daily dosing intervals could be a safe alternative to current practice.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a vrozené poruchy metabolismu kovů $x farmakoterapie $x genetika $7 D008664
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a kojenec $7 D007223
- 650 12
- $a xanthindehydrogenasa $x nedostatek $x metabolismus $x genetika $7 D014968
- 650 _2
- $a sulfitoxidasa $x nedostatek $x metabolismus $x genetika $7 D050876
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a molybdenové kofaktory $7 D000090006
- 650 _2
- $a metaloproteiny $x nedostatek $x metabolismus $x genetika $7 D008667
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a organofosforové sloučeniny $7 D009943
- 650 _2
- $a pteriny $7 D011622
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a kazuistiky $7 D002363
- 700 1_
- $a Barvíková, K $u Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
- 700 1_
- $a Wu, H T $u Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK
- 700 1_
- $a Horman, A $u Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Health Innovation Manchester, Manchester, UK; Department of Chemical Pathology, Great Ormond Street Hospital, London, UK
- 700 1_
- $a Emmett, E $u Biochemical Sciences, Synnovis, Guys & St Thomas' NHS Foundation Trust, London, UK
- 700 1_
- $a Kožich, V $u Department of Pediatrics and Inherited Metabolic Disorders, Charles University-First Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic
- 773 0_
- $w MED00006573 $t Molecular genetics and metabolism $x 1096-7206 $g Roč. 143, č. 1-2 (2024), s. 108563
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39168057 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206105133 $b ABA008
- 999 __
- $a ok $b bmc $g 2263708 $s 1240131
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 143 $c 1-2 $d 108563 $e 20240810 $i 1096-7206 $m Molecular genetics and metabolism $n Mol Genet Metab $x MED00006573
- LZP __
- $a Pubmed-20250121
